Richard L. Simmons, M.D.; Allen W. Moberg, M.D.; Carl M. Kjellstrand, M.D.; John S. Najarian, M.D.
This content is PDF only. Please click on the PDF icon to access.
Our previous studies have shown that an antiglobulin to cultured human lymphoblasts can prolong skin allograft survival in man across strong histocompatibility barriers. When lymphoblasts are utilized as the antigen, the product does not require absorption by either red blood cells or platelets, it does not bind to glomerular basement membranes, and it can be administered intravenously in large doses for prolonged periods. Thirty-five consecutive recipients of cadaver renal allografts received 0 to 30 mg/kg body weight of antilymphoblast globulin. In addition, standard doses of azathioprine and prednisone were administered to all patients, regardless of the antiglobulin dose. Of five
Simmons RL, Moberg AW, Kjellstrand CM, et al. Antilymphoblast Globulin in Man: Survival of Unrelated Kidney Allografts.. Ann Intern Med. 1971;74:833. doi: 10.7326/0003-4819-74-5-833_2
Download citation file:
Published: Ann Intern Med. 1971;74(5):833.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use